Pharmacodynamic, prognostic, and predictive biomarkers in severe and critical COVID-19 patients treated with sirukumab

Abstract We examined candidate biomarkers for efficacy outcomes in hospitalized COVID-19 patients who were treated with sirukumab, an IL-6 neutralizing antibody, in a randomized, double-blind, placebo-controlled, phase 2 trial. Between May 2020 and March 2021, 209 patients were randomized (sirukumab...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kim Thys, Matthew J. Loza, Linghua Lynn, Katleen Callewaert, Lisa Varma, Marjolein Crabbe, Liesbeth Van Wesenbeeck, Erika Van Landuyt, Sandra De Meyer, Jeroen Aerssens, Inge Verbrugge
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-10-01
Serie:	Scientific Reports
Soggetti:	COVID-19 IL-6 IL-4 Biomarkers Inflammation
Accesso online:	https://doi.org/10.1038/s41598-024-74196-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!